Accurate measurement of kidney function is fundamental to the clinical care of patients with cirrhosis. Assessment of kidney function in this context informs medication choices, risk prediction, and candidacy and prioritization for liver and/or dual-organ liver-kidney transplant. However, it is well-established that serum creatine (sCr) and sCr-based estimations of glomerular filtration rate (eGFR) are inaccurate in this population, to varying degrees, due in part to the decreased hepatic synthesis of creatine and lower production of creatinine from skeletal muscle.^1,2 For these reasons, investigations in search of the optimal metric to capture an accurate GFR in patients with cirrhosis have been a high priority.

中文翻译：

---

估计肝硬化肾小球滤过率：需要临床意识的可变科学

准确测量肾功能是肝硬化患者临床护理的基础。在这种情况下对肾功能的评估可为药物选择、风险预测以及肝脏和/或双器官肝肾移植的候选资格和优先次序提供信息。然而，公认的是，基于血清肌酸 (sCr) 和基于 sCr 的肾小球滤过率 (eGFR) 估计值在该人群中是不准确的，部分原因是肌酸的肝合成减少和肌酐生成减少来自骨骼肌。^1,2出于这些原因，寻找最佳指标以捕获肝硬化患者准确 GFR 的调查一直是当务之急。